Trump Strikes Landmark Deal To Cut Weight-Loss Drug Prices And Expand Coverage

President Donald Trump has announced a historic deal with pharmaceutical giants Novo Nordisk and Eli Lilly to lower the cost of GLP-1 weight-loss drugs and expand access across the United States.

The agreement, revealed Thursday at the White House, aims to make drugs like Wegovy, Zepbound, and Mounjaro more affordable for Americans struggling with obesity and related conditions.

Under the plan, cash-paying patients will pay around $350 per month, with a goal to reduce the price to $245 within two years. For Medicare beneficiaries, co-pays will be capped at $50 per month, marking the first time many seniors will gain coverage for GLP-1 treatments.

Future oral versions of these medications, once approved, are expected to cost about $149 a month, further widening affordability.

“This is about giving people access to life-changing medication, making sure Americans can afford the care they deserve.”

The deal also broadens eligibility under Medicare and Medicaid to include individuals with obesity-related conditions such as heart disease, pre-diabetes, and kidney disease.

While health experts have praised the move as a major win for public access, some analysts caution that even the reduced prices may still be high for uninsured Americans, and details of how private insurers will respond remain to be seen.

Still, the agreement marks one of the most significant steps toward affordable obesity care in U.S. history, potentially transforming how millions manage their weight and related health risks.